Cargando…

JAK inhibitors and COVID-19

During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levy, Gabriel, Guglielmelli, Paola, Langmuir, Peter, Constantinescu, Stefan N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035837/ https://www.ncbi.nlm.nih.gov/pubmed/35459733 http://dx.doi.org/10.1136/jitc-2021-002838

Ejemplares similares

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective
por: Staerk, Judith, et al.
Publicado: (2012)

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013)

Correction: JAK inhibitors and COVID-19
Publicado: (2023)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
por: Vannucchi, Alessandro M., et al.
Publicado: (2020)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2019)

JAK-STAT pathway inhibitors in dermatology()
por: Miot, Hélio Amante, et al.
Publicado: (2023)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
por: Kvist-Hansen, Amanda, et al.
Publicado: (2019)

A Comprehensive Overview of Globally Approved JAK Inhibitors
por: Shawky, Ahmed M., et al.
Publicado: (2022)

JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis
por: Chen, Chong-xiang, et al.
Publicado: (2021)

Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
por: Bertsias, George
Publicado: (2020)

Under Development JAK Inhibitors for Dermatologic Diseases
por: Sideris, Nikolaos, et al.
Publicado: (2020)

Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
por: Thoms, Brendan L., et al.
Publicado: (2022)

Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19
por: Thoms, Brendan Lawless, et al.
Publicado: (2021)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
por: Kuykendall, Andrew T., et al.
Publicado: (2020)

Germline Counterparts of Oncogenic Mutations: Who Gives a JAK?
por: Mead, Adam J., et al.
Publicado: (2013)

The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders
por: Caiazzo, Giuseppina, et al.
Publicado: (2023)

JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors
por: Dusa, Alexandra, et al.
Publicado: (2010)

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
por: Fragoulis, George E, et al.
Publicado: (2019)

Recent advances in JAK inhibitors for the treatment of metabolic syndrome
por: Collotta, Debora, et al.
Publicado: (2023)

A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens
por: Constantinescu, Stefan N
Publicado: (2009)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
por: Constantinescu, Stefan N., et al.
Publicado: (2021)

Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib
por: Chimenti, Maria Sole, et al.
Publicado: (2021)

Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD
por: Pippis, Elleni J, et al.
Publicado: (2020)

JAK Inhibitors and Oxidative Stress Control
por: Charras, Amandine, et al.
Publicado: (2019)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment
por: Dudek, Patrycja, et al.
Publicado: (2021)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023)

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

JAK inhibitors for refractory lymphoma
por: Kimura, Hiroshi
Publicado: (2018)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

JAK1 Selective inhibitors
por: Edwards, Christopher
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7ms571elv2voafivg8s2sre6p1